Tprg1l, also known as Mover, is a protein-coding gene. It has multiple functions including regulating the probability of neurotransmitter release in neurons, being associated with lipid droplets in astrocytes, and participating in signaling pathways like NF-κB [2,5,6,7]. It seems to play a role in lipid-related neurological disorders and may be involved in cellular inflammatory responses [2,3].

In gallbladder cancer, tRF-3013b inhibits cell proliferation by targeting Tprg1l and repressing NF-κB. Decreased tRF-3013b expression is correlated with poor overall survival in GBC patients [1]. In the context of human cytomegalovirus infection, the long non-coding RNA1.2 suppresses extracellular release of the pro-inflammatory cytokine IL-6 by blocking NF-κB activation, and Tprg1L upregulation activates NF-κB, leading to increased IL-6 expression [4].

In conclusion, Tprg1l is involved in multiple biological processes such as synaptic transmission, lipid droplet regulation in astrocytes, and inflammatory responses. Its role in diseases like gallbladder cancer and during viral infections, as revealed through functional studies, highlights its importance in understanding disease mechanisms and potentially developing new therapeutic strategies.